Kyle Connors practices in the life sciences and intellectual property transactions groups at Ropes & Gray, advising clients on a broad range of matters including complex licensing arrangements, collaborations, mergers & acquisitions, commercial agreements, and drug pricing strategies.
Prior to joining the firm, Kyle participated in the Patent and Licensing Clinic, where he worked on patent prosecution and licensing matters for the UVA Licensing and Ventures Group. He also worked as a legal intern in the Office of the General Counsel in the Department of Health and Human Services. As an undergraduate student, Kyle worked as a research assistant at an analytical chemistry laboratory and at a contract manufacturer of clinical trial vaccines and therapies.
Experience
- Represented Pfizer in its
- Strategic partnership with Flagship Pioneering to explore opportunities to develop 10 single-asset programs by leveraging Flagship's ecosystem of companies and biotechnology platforms, with Pfizer having an option to acquire each development program and Flagship and its platform companies eligible to receive up to $700M in milestones and royalties for each successfully commercialized program
- $11.6 billion acquisition of Biohaven Pharmaceuticals
- $6.7 billion acquisition of Arena Pharmaceuticals
- $25 million collaboration with and investment in UK-based biotechnology company CellCentric
- Represented a global biopharmaceutical company in its partnership with a national provider of retail pharmacy and healthcare services.
- Represented uniQure N.V. in its global licensing agreement with Apic Bio worth up to $55 million for a clinical stage gene therapy program to treat amyotrophic lateral sclerosis (ALS).
- Advised a global biopharmaceutical company in a collaboration agreement with a research institute to develop a treatment for a novel viral disease.
- Advises on academic licenses, clinical and commercial supply agreements, manufacturing agreements, sponsored research agreements, clinical trial agreements, master services agreements, and material transfer agreements for clients such as Solid Biosciences, Walden Biosciences, and Psivant Therapeutics.
- Advises biopharmaceutical companies on drug pricing matters related to the Inflation Reduction Act.